Sign in →

Test Code IMRGF Imatinib Mesylate Responsive Genes, FISH

Useful For

Detecting a neoplastic clone associated with the common chromosome abnormalities seen in patients with acute leukemia or other myeloid malignancies

                             

Tracking known chromosome abnormalities and response to therapy in patients with myeloid malignancies

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
_PBCT Probe, +2 No, (Bill Only) No
_PADD Probe, +1 No, (Bill Only) No
_PB02 Probe, +2 No, (Bill Only) No
_PB03 Probe, +3 No, (Bill Only) No
_IL25 Interphases, <25 No, (Bill Only) No
_I099 Interphases, 25-99 No, (Bill Only) No
_I300 Interphases, >=100 No, (Bill Only) No

Testing Algorithm

This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.

 

Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred

 

This assay includes testing for the following abnormalities using the probes listed:

ABL2 (1q25) rearrangement

FIP1L1/CHIC2/PDGFRA (4q12) rearrangement (CHIC2 deletion)

PDGFRB (5q33) rearrangement                 

ABL1 (9q34) rearrangement

 

If the patient is being tracked for known abnormalities, indicate which probes should be used.

Method Name

Fluorescence In Situ Hybridization (FISH)

Reporting Name

Imatinib Mesylate Resp Genes, FISH

Specimen Type

Varies


Specimen Required


Provide a reason for referral with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.

 

Advise Express Mail or equivalent if not on courier service.

 

Submit only 1 of the following specimens:

 

Specimen Type: Blood

Container/Tube: Green top (sodium heparin)

Specimen Volume: 7-10 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Other anticoagulants are not recommended and are harmful to the viability of the cells.

 

Specimen Type: Bone marrow

Container/Tube: Green top (sodium heparin)

Specimen Volume: 1-2 mL

Collection Instructions:

1. Invert several times to mix bone marrow.

2. Other anticoagulants are not recommended and are harmful to the viability of the cells.


Specimen Minimum Volume

Blood: 2 mL/Bone Marrow: 1 mL

Specimen Stability Information

Specimen Type Temperature Time
Varies Ambient (preferred)
  Refrigerated 

Clinical Information

Myeloid neoplasms are primary disorders of the bone marrow cells. These malignancies encompass several entities with extremely varied clinical courses, including acute myeloid leukemias (AML), chronic myeloproliferative disorders (CMPD), and myelodysplastic syndromes. The underlying genetic mechanisms associated with these malignancies are varied and only a portion of the genetic abnormalities have targeted therapies clinically available.

            

One group of genes, including ABL1 (Abelson murine leukemia viral oncogene homolog 1), ABL2 (Abelson murine leukemia viral oncogene homolog 2), PDGFRA (platelet-derived growth factor receptor, alpha), and PDGFRB (platelet-derived growth factor receptor, beta) can be inappropriately activated via various genetic mechanisms and result in overexpression of their tyrosine kinase activity. Tyrosine kinase activity plays an important role in cellular signaling, division, and differentiation; overexpression may cause some cancers. The myeloid malignancies associated with these aberrantly expressed genes include AML, chronic myelogenous leukemia (CML), hypereosinophilic syndrome/systemic mast cell disease (HES/SMCD), and atypical CMPD. These translocations can also be seen in lymphoid neoplasms, including acute lymphoblastic leukemia (ALL) and lymphomas, and they can also possess a varied genetic etiology. Several clinical studies have demonstrated that the malignancies displaying overexpression of these genes are responsive to imatinib mesylate, a drug that specifically targets these genes.

Reference Values

An interpretive report will be provided.

Day(s) and Time(s) Performed

Samples processed Monday through Sunday. Results reported Monday through Friday, 8 a.m.-5 p.m. CST.

Analytic Time

7 days

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

88271x2, 88291 – DNA probe, each (first probe set), Interpretation and report

88271x2 – DNA probe, each; each additional probe set (if appropriate)

88271x1 – DNA probe, each; coverage for sets containing 3 probes (if appropriate)

88271x2 – DNA probe, each; coverage for sets containing 4 probes (if appropriate)

88271x3 – DNA probe, each; coverage for sets containing 5 probes (if appropriate)

88274 w/modifier 52 – Interphase in situ hybridization, <25 cells, each probe set (if appropriate)

88274 – Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)     

88275 – Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
IMRGF Imatinib Mesylate Resp Genes, FISH In Process

 

Result ID Test Result Name Result LOINC Value
51811 Result Summary 50397-9
51813 Interpretation 69965-2
51812 Result Table No LOINC Needed
54532 Result In Process
CG659 Reason for Referral 42349-1
CG660 Specimen 31208-2
51814 Source 31208-2
51815 Method 49549-9
53430 Additional Information 48767-8
55276 Disclaimer 62364-5
51816 Released By 18771-6

NY State Approved

Yes